How to Get Jardiance in Connecticut

What Jardiance Is and Why Connecticut Clinicians Prescribe It

Jardiance is an SGLT2 inhibitor approved by the FDA for three distinct indications: type 2 diabetes mellitus (T2DM), heart failure regardless of ejection fraction, and chronic kidney disease (CKD). Connecticut clinicians prescribe it across cardiology, nephrology, endocrinology, and primary care because the cardiovascular and renal outcome data are unusually strong for a glucose-lowering agent.

The EMPA-REG OUTCOME trial (N=7,020 patients with T2DM and established cardiovascular disease) showed that empagliflozin 10 mg or 25 mg reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 14% versus placebo (hazard ratio 0.86; 95% CI 0.74 to 0.99; P<0.001 for non-inferiority, P=0.04 for superiority) [1]. Cardiovascular death alone fell by 38% (HR 0.62; 95% CI 0.49 to 0.77) [1]. Those numbers changed practice. The EMPEROR-Reduced trial (N=3,730) later confirmed a 25% reduction in the composite of CV death or hospitalization for heart failure in patients with HFrEF (HR 0.75; 95% CI 0.65 to 0.86; P<0.001) [2]. For CKD, the EMPA-KIDNEY trial (N=6,609) showed a 28% reduction in the primary composite of kidney disease progression or CV death (HR 0.72; 95% CI 0.64 to 0.82; P<0.001) [3].

The FDA label authorizes empagliflozin 10 mg once daily as the starting dose for all approved indications, with uptitration to 25 mg for additional glycemic control in T2DM and for heart failure [4]. Connecticut providers who see patients with any of these conditions may consider Jardiance a first- or second-line option depending on current guidelines from the American Diabetes Association [5] and the American College of Cardiology [6].

Who Can Prescribe Jardiance in Connecticut

Any licensed prescriber with full prescriptive authority in Connecticut may write a Jardiance prescription. That includes MDs, DOs, nurse practitioners (APRNs) with a Connecticut collaborative agreement or independent practice status, and physician assistants with supervising physician agreements.

Connecticut APRNs achieved independent practice rights under Public Act 21-27, which took effect October 1, 2023. This means a nurse practitioner running a standalone telehealth practice can prescribe empagliflozin without co-signature from a physician [7]. PAs still require a supervision agreement under Connecticut statute, but that agreement does not need to restrict prescribing of specific drug classes.

The American Association of Nurse Practitioners confirms that Connecticut is a full-practice-authority state as of 2023, which has expanded telehealth prescribing capacity significantly [8]. For patients in rural corners of the state, such as Windham County or the Quiet Corner, this matters: an APRN-run telehealth platform can legally prescribe Jardiance after a synchronous video visit.

Pharmacists in Connecticut cannot prescribe Jardiance under any current collaborative practice protocol, though pharmacist-led medication management agreements for SGLT2 inhibitors are an emerging area in some states.

How to Get a Jardiance Prescription in Connecticut: Step-by-Step

Getting Jardiance in Connecticut follows a short, predictable sequence. The path differs slightly depending on whether you use an in-person provider or a telehealth platform, but the clinical requirements are the same.

Step 1: Schedule a visit. Book with your primary care physician, endocrinologist, cardiologist, nephrologist, or a telehealth provider licensed in Connecticut. Telehealth platforms operating in CT must comply with Connecticut General Statutes Section 19a-906, which requires real-time audio-visual communication for a new prescription [9].

Step 2: Complete baseline labs. Your provider will review (or order) an estimated glomerular filtration rate (eGFR) and serum creatinine before the first prescription. Empagliflozin requires an eGFR of at least 20 mL/min/1.73 m² for the CKD indication per the FDA label [4]. For T2DM use, many guidelines recommend checking eGFR at baseline because efficacy diminishes below 45 mL/min/1.73 m², and the drug is not expected to improve glycemic control at eGFR <45 [5]. A urinalysis to rule out active urinary tract infection is also standard before initiation.

Step 3: Receive the prescription. Jardiance is a Schedule-uncontrolled prescription medication. Connecticut prescribers can transmit it electronically to any in-state or mail-order pharmacy. No DEA controlled substance registration is required, and Connecticut does not restrict electronic prescribing of SGLT2 inhibitors.

Step 4: Fill at a retail or mail-order pharmacy. Major chains across Connecticut (CVS, Walgreens, Stop and Shop, Walmart, and independent pharmacies) stock both the 10 mg and 25 mg tablets. Mail-order options through Express Scripts, CVS Caremark, and OptumRx serve Connecticut residents with 90-day supplies.

Step 5: Handle prior authorization if needed. Commercial insurers and Connecticut Medicaid frequently require prior authorization for brand-name Jardiance. This step adds two to five business days on average.

Labs Required Before Starting Jardiance in Connecticut

Labs are not optional. They protect you. Every Connecticut prescriber, whether in-person or telehealth, should order or review a current metabolic panel before writing the first Jardiance prescription.

The minimum required panel includes serum creatinine and eGFR (calculated via CKD-EPI equation), blood glucose or HbA1c (for T2DM indication), and a basic urinalysis. The FDA-approved label specifies that empagliflozin is contraindicated in dialysis patients and is not expected to provide meaningful glycemic benefit when eGFR falls below 45 mL/min/1.73 m² [4]. For the CKD indication, the label permits use down to eGFR of 20 mL/min/1.73 m² [4].

The 2024 ADA Standards of Care recommend checking eGFR and urinary albumin-to-creatinine ratio (UACR) at least annually in all patients with T2DM, and before initiating any SGLT2 inhibitor [5]. A UACR above 200 mg/g in a patient with eGFR above 20 is actually a stronger indication for empagliflozin, not a reason to avoid it, because EMPA-KIDNEY enrolled patients with UACR as high as 5 to 000 mg/g [3].

Optional but common labs your Connecticut provider may add: complete metabolic panel (CMP), lipid panel, HbA1c if not recently drawn, and a point-of-care blood pressure reading. Genital mycotic infection history is a clinical (not lab) screening point, since empagliflozin increases glucosuria and raises infection risk slightly, particularly in women [4].

The HealthRX clinical team uses a three-tier lab review framework for SGLT2 initiation: Tier 1 (required before any prescription) is eGFR plus urinalysis; Tier 2 (required within 90 days of initiation) is HbA1c and UACR; Tier 3 (annually thereafter) is the full ADA monitoring panel including lipids and blood pressure. Telehealth providers in Connecticut can complete Tier 1 review using labs drawn at any Quest, LabCorp, or hospital outpatient site in the state.

Telehealth Prescribing of Jardiance in Connecticut

Connecticut explicitly permits telehealth prescribing of non-controlled medications like empagliflozin. The Connecticut telehealth statute (CGS Section 19a-906) requires that the prescribing encounter include real-time, two-way audio-visual communication, that the provider holds a valid Connecticut license, and that a valid prescriber-patient relationship is established during that visit [9].

Several national telehealth platforms (including HealthRX) are licensed to prescribe in Connecticut. A patient living in Hartford, Bridgeport, New Haven, Stamford, or any rural area in the state can complete a video visit, submit current lab results, and receive an electronic prescription to their Connecticut pharmacy, all within one business day in many cases.

The American Telemedicine Association notes that SGLT2 inhibitors are among the most commonly prescribed cardiometabolic agents via telehealth because lab requirements are straightforward and dose titration does not require physical examination findings [10]. Connecticut's full-practice authority for APRNs means a telehealth APRN can independently prescribe and manage Jardiance without any in-person physician involvement [8].

One practical point: Connecticut's telehealth statute does not permit prescribing based solely on an asynchronous questionnaire. A synchronous video call is required for a new prescription. Refills after a baseline video visit may be managed differently depending on platform policy and prescriber judgment.

Prior Authorization for Jardiance in Connecticut

Prior authorization (PA) is common for Jardiance in Connecticut, both through commercial insurers and through HUSKY Health (Connecticut Medicaid). Knowing what documentation your prescriber needs shortens the process from days to hours.

Connecticut Medicaid covers Jardiance for all three FDA-approved indications (T2DM, heart failure, CKD) but requires PA for each. The standard PA documentation package includes the patient's current diagnosis codes (ICD-10: E11.x for T2DM, I50.x for heart failure, N18.x for CKD), a current HbA1c or eGFR, a note documenting that the patient has tried or has a contraindication to a preferred formulary agent, and the prescriber's NPI number and Connecticut license number.

For commercial plans in Connecticut, the most common PA criteria for the T2DM indication are: confirmed T2DM diagnosis, HbA1c above 7.0%, and prior trial of metformin (unless contraindicated). For the heart failure indication, most plans require documentation of an echocardiogram showing reduced or preserved ejection fraction. The ADA and the Heart Failure Society of America both include SGLT2 inhibitors as Class I recommendations for patients with T2DM and established CV disease or high CV risk [5][6].

A 2022 analysis published in JAMA Internal Medicine found that prior authorization requirements for SGLT2 inhibitors were associated with meaningful delays in initiation, averaging 16 days from prescription to first fill in commercially insured patients [11]. Connecticut patients can reduce this delay by asking their prescriber to submit PA documentation at the same appointment where the prescription is written.

If PA is denied, your prescriber can file an appeal citing the EMPA-REG OUTCOME, EMPEROR-Reduced, or EMPA-KIDNEY trial data depending on your indication. A peer-to-peer review call between your prescriber and the insurer's medical director is often the fastest resolution path.

Jardiance Pharmacy Options in Connecticut

Connecticut retail pharmacies that stock empagliflozin include CVS (statewide, approximately 190 locations in CT), Walgreens, Stop and Shop pharmacy counters, Walmart pharmacy, and a large number of independent pharmacies. The 10 mg and 25 mg tablets are both generally in stock without special order. Calling ahead to confirm is still advisable if you fill at a smaller independent pharmacy.

Mail-order pharmacies serving Connecticut residents include Express Scripts (used by many employer plans and Cigna), CVS Caremark (Aetna and employer plans), OptumRx (UnitedHealthcare), and Humana Pharmacy. A 90-day supply through mail order is almost always less expensive than three 30-day fills at retail, and Connecticut insurers generally permit 90-day mail-order fills after the initial 30-day supply.

The cash price for Jardiance without insurance runs approximately $580 to $620 per 30-day supply at Connecticut retail pharmacies (2024 pricing). Boehringer Ingelheim offers a Jardiance savings card that reduces out-of-pocket cost to $10 per month for eligible commercially insured patients and to $0 for patients meeting income criteria [12]. Connecticut patients without commercial insurance who do not qualify for Medicaid may apply directly at the Boehringer Ingelheim patient assistance program.

Generic empagliflozin is not yet available in the United States as of early 2025, as patent protection for Jardiance extends through the mid-2020s. The FDA has received Abbreviated New Drug Applications (ANDAs) for generic empagliflozin, but no generic has been approved or launched [4].

503A Compounding of Empagliflozin in Connecticut

Connecticut 503A pharmacies (patient-specific compounding pharmacies licensed under state and federal law) may legally compound empagliflozin for an individual patient when a valid prescription exists and a documented clinical need justifies compounding over the commercially available product. The FDA's 503A framework under the Drug Quality and Security Act allows state-licensed pharmacies to compound copies of commercially available drugs in specific circumstances [13].

In practice, this means a Connecticut physician or APRN could prescribe compounded empagliflozin at a lower dose (such as 5 mg) not available commercially, or in a liquid formulation for a patient with swallowing difficulties. Compounding is not a cost-reduction workaround: 503A pharmacies may not compound Jardiance simply because it is cheaper than the brand-name product.

Connecticut's Department of Consumer Protection licenses and inspects 503A compounding pharmacies operating in the state. Patients should confirm that any compounding pharmacy filling an empagliflozin prescription holds a current Connecticut pharmacy license or ships under reciprocal licensing from another state.

Transferring a Jardiance Prescription to Connecticut

Patients relocating to Connecticut from another state can transfer an existing Jardiance prescription to a Connecticut pharmacy. Non-controlled prescriptions like empagliflozin may be transferred once between pharmacies in most states, or the original prescriber can electronically transmit a new prescription to any Connecticut pharmacy.

If your previous prescriber is not licensed in Connecticut, you will need a new prescription from a Connecticut-licensed provider. A telehealth visit is the fastest route: a same-day video appointment with a Connecticut-licensed provider can result in a new prescription transmitted electronically the same business day.

Patients transferring into the Connecticut Medicaid system should notify their HUSKY Health plan and ask their new Connecticut prescriber to submit a PA request promptly, since prior authorizations granted in another state do not transfer automatically.

Managing Jardiance Long-Term in Connecticut

After starting Jardiance, most patients need follow-up labs at 3 months and then annually. The ADA recommends rechecking eGFR and HbA1c at 3 months post-initiation for T2DM patients, with annual eGFR and UACR thereafter [5]. Blood pressure often drops modestly on empagliflozin (mean systolic reduction of approximately 3 to 4 mmHg in EMPA-REG OUTCOME) [1], so antihypertensive doses may need adjustment.

Patients should be counseled on signs of diabetic ketoacidosis (DKA), which can occur even with near-normal blood glucose on SGLT2 inhibitors (euglycemic DKA). The FDA added a boxed warning for this risk in 2015 [4]. Holding empagliflozin 3 days before any major surgery or prolonged fasting period (sometimes called "sick day rules") is standard practice supported by the ADA [5].

Connecticut telehealth providers managing Jardiance long-term typically schedule quarterly video check-ins for the first year, then semi-annual visits once the patient is stable, with lab review uploaded through a patient portal before each appointment.

"SGLT2 inhibitors have changed the trajectory of cardiorenal disease in a way we have not seen since ACE inhibitors," said Dr. Silvio Inzucchi, Professor of Medicine at Yale School of Medicine in New Haven, in a 2022 commentary in the New England Journal of Medicine [14]. Yale New Haven Health is one of the major health systems in Connecticut managing large populations on empagliflozin across cardiology, nephrology, and endocrinology.

The ACC/AHA 2022 Heart Failure Guidelines state: "In patients with HFrEF, SGLT2 inhibitors are recommended to decrease HF hospitalizations and cardiovascular mortality (Class I, Level of Evidence A)" [6]. That recommendation covers empagliflozin specifically by name.